Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging therapies for inv(16) AML.

Literature DB >> 33821975

Emerging therapies for inv(16) AML.

Sridevi Surapally¹, Daniel G Tenen^2,3, John A Pulikkan^1,4.

Abstract

The core binding factor composed of CBFβ and RUNX subunits plays a critical role in most hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion oncogene CBFβ-SMMHC expressed in AML with the chromosome inversion inv(16)(p13q22) acts as a driver oncogene in hematopoietic stem cells and induces AML. This review focuses on novel insights regarding the molecular mechanisms involved in CBFβ-SMMHC-driven leukemogenesis and recent advances in therapeutic approaches to target CBFβ-SMMHC in inv(16) AML.

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 33821975 PMCID： PMC8120144 DOI： 10.1182/blood.2020009933

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

80 in total

Review 1. Core-binding factors in haematopoiesis and leukaemia.

Authors: Nancy A Speck; D Gary Gilliland
Journal: Nat Rev Cancer Date: 2002-07 Impact factor: 60.716

2. Dynamic combinatorial interactions of RUNX1 and cooperating partners regulates megakaryocytic differentiation in cell line models.

Authors: Niv Pencovich; Ram Jaschek; Amos Tanay; Yoram Groner
Journal: Blood Date: 2010-10-19 Impact factor: 22.113

3. Runx3 deficiency results in myeloproliferative disorder in aged mice.

Authors: Chelsia Qiuxia Wang; Lena Motoda; Masanobu Satake; Yoshiaki Ito; Ichiro Taniuchi; Vinay Tergaonkar; Motomi Osato
Journal: Blood Date: 2013-06-05 Impact factor: 22.113

4. CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Authors: John Anto Pulikkan; Mahesh Hegde; Hafiz Mohd Ahmad; Houda Belaghzal; Anuradha Illendula; Jun Yu; Kelsey O'Hagan; Jianhong Ou; Carsten Muller-Tidow; Scot A Wolfe; Lihua Julie Zhu; Job Dekker; John Hackett Bushweller; Lucio Hernán Castilla
Journal: Cell Date: 2018-06-28 Impact factor: 41.582

5. RUNX1 and inv(16) are frenemies in AML.

Authors: Sridhar Rao
Journal: Blood Date: 2020-11-19 Impact factor: 22.113

6. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.

Authors: Hong Guo; Ou Ma; Nancy A Speck; Alan D Friedman
Journal: Blood Date: 2012-03-26 Impact factor: 22.113

7. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.

Authors: Tao Zhen; Yaqiang Cao; Gang Ren; Ling Zhao; R Katherine Hyde; Guadalupe Lopez; Dechun Feng; Lemlem Alemu; Keji Zhao; P Paul Liu
Journal: Blood Date: 2020-11-19 Impact factor: 22.113

8. CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia.

Authors: Gaëlle Cordonnier; Amit Mandoli; Nicolas Cagnard; Guillaume Hypolite; Ludovic Lhermitte; Els Verhoeyen; Vahid Asnafi; Niall Dillon; Elizabeth Macintyre; Joost H A Martens; Jonathan Bond
Journal: Cell Rep Date: 2020-01-14 Impact factor: 9.423

9. CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.

Authors: Melinda A Biernacki; Kimberly A Foster; Kyle B Woodward; Michael E Coon; Carrie Cummings; Tanya M Cunningham; Robson G Dossa; Michelle Brault; Jamie Stokke; Tayla M Olsen; Kelda Gardner; Elihu Estey; Soheil Meshinchi; Anthony Rongvaux; Marie Bleakley
Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808

10. BRWD1 orchestrates epigenetic landscape of late B lymphopoiesis.

Authors: Malay Mandal; Mark Maienschein-Cline; Patrick Maffucci; Margaret Veselits; Domenick E Kennedy; Kaitlin C McLean; Michael K Okoreeh; Sophiya Karki; Charlotte Cunningham-Rundles; Marcus R Clark
Journal: Nat Commun Date: 2018-09-24 Impact factor: 14.919

2 in total

1. PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia.

Authors: Lulu Wang; Wei Wang; Hannah C Beird; Xueqian Cheng; Hong Fang; Guilin Tang; Gokce A Toruner; C Cameron Yin; M James You; Ghayas C Issa; Gautam Borthakur; Guang Peng; Joseph D Khoury; L Jeffrey Medeiros; Zhenya Tang
Journal: Genes (Basel) Date: 2022-07-29 Impact factor: 4.141

2. Explainable artificial intelligence for precision medicine in acute myeloid leukemia.

Authors: Marian Gimeno; Edurne San José-Enériz; Sara Villar; Xabier Agirre; Felipe Prosper; Angel Rubio; Fernando Carazo
Journal: Front Immunol Date: 2022-09-29 Impact factor: 8.786

2 in total